Citius Oncology, Inc. (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. In August 2024, the U.S. Food and Drug Administration (FDA) approved LYMPHIR™ (denileukin diftitox-cxdl), our targeted immune therapy for patients with Stage 1-3 relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Citius Oncology, Inc. is a majority-owned publicly-traded subsidiary of Citius Pharmaceuticals, Inc
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline consisting of candidate therapeutics in Cutaneous T-Cell Lymphoma (CTCL), other oncology and adjunct cancer care, anti-infectives, stem cell therapy and unique prescription products.